Researchers at the University of Cambridge have completed the first human trial of a vaccine whose core component was designed entirely by artificial intelligence, with initial safety tests in 39 volunteers proving successful. Rather than targeting a single circulating strain, the AI analysed genetic sequences from across the entire coronavirus family to construct a "super-antigen" capable of training the immune system against all known variants — including animal-borne strains that could spark future outbreaks. A follow-up study of around 200 participants will assess immune response, while the same technology is already being applied to develop a universal flu vaccine and a candidate against H5N1 bird flu, with experts describing the approach as a potential "pivotal leap" that could end the need for annual vaccine updates.